Nick Cavros, MD, cardiologist at Cardiovascular Institute of
the South, is the first in the world to utilize the Closys HD device in the CloSys™ Closure System IDE Trial. Dr. Cavros serves as the Principal
Investigator for this trial at Lafayette General Medical Center.
The Closys™
Closure System, manufactured by the Closys Corporation, uses a patient’s own
blood following an interventional procedure to quickly close the artery at the insertion
site. No foreign materials are used and no object is left behind in
the body.
The trial aims to
show that this device allows for the safety and
reliability of manual compression with an additional benefit of a faster
recovery time.
Dr. Cavros explains, "It is so important to finish an intervention with
the right closure device. The
Closys HD device is easy to use, does not create complications, and does not
leave anything behind!”
Dr. Cavros added, "As the Principal Investigator of the first Closys™ Closure System trial site, I am
very pleased to be an important part of the CloSys trial. I look forward to what I believe will
be a positive trial.”
"CloSys is privileged to be able to begin this trial at a
high profile institution such as Lafayette General and to be able to have the
device tested by the highly regarded cardiologists of the Cardiovascular Institute
of the South,” states Ms. Gervaise Wilhelm, CEO of CloSys Corporation.
For more information on the Closys HD device or the Closys Corporation,
please visit www.closyscorp.com. For more information about Dr. Cavros
and CIS, please visit www.cardio.com.
